Angiotensin II dosage in published studies and labels

These are the doses used for Angiotensin II in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.

Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.

Last checked against primary sources: November 7, 2026

Studied regimens and sources

Angiotensin II has an FDA-approved human dosage only as Giapreza, a hospital infusion to raise blood pressure in adults with septic or other distributive shock. The label starts at 20 ng/kg/min by continuous intravenous infusion, titrated every 5 minutes by up to 15 ng/kg/min, with no more than 80 ng/kg/min in the first 3 hours and no more than 40 ng/kg/min for maintenance.

FDA Approved

Dosage evidence summary for Angiotensin II
Human dosing established	Yes
Route	Intravenous
Frequency	Continuous intravenous infusion
Duration studied	Until the underlying shock has improved, then tapered
Titration	Start at 20 ng/kg/min; raise as often as every 5 minutes by up to 15 ng/kg/min to the target blood pressure; do not exceed 80 ng/kg/min in the first 3 hours or 40 ng/kg/min for maintenance; doses as low as 1.25 ng/kg/min may be used. Once shock improves, reduce every 5 to 15 minutes by up to 15 ng/kg/min.
Half-life	Less than one minute in plasma after intravenous administration (Giapreza label)
Evidence level	FDA Approved
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Angiotensin II, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
FDA label — Giapreza, septic or other distributive shockFDA-approved label · FDA prescribing information	Adults with septic or other distributive shock	20 ng/kg/min to start; maximum 80 ng/kg/min in the first 3 hours, then no more than 40 ng/kg/min	Intravenous infusion, diluted in 0.9% sodium chloride; central line recommended	Continuous	Titrated, then tapered	Increased blood pressure; studied in ATHOS-3, 321 adults who stayed hypotensive despite fluids and vasopressors	GIAPREZA (angiotensin II) injection — FDA prescribing information, DailyMed

Where sources disagree

Angiotensin II is dosed in nanograms per kilogram per minute as a monitored intravenous infusion; in ATHOS-3 it was given on top of background vasopressor therapy. The label covers no other use or route.
The label warns of blood clots: in ATHOS-3, arterial and venous thrombotic and thromboembolic events occurred in 13% of patients on Giapreza against 5% on placebo, mainly deep vein thrombosis, and the label calls for clot prevention during treatment.
Giapreza is supplied as a ready-made solution (0.5 mg/mL or 2.5 mg/mL) that is diluted in saline to 5,000 or 10,000 ng/mL before infusion; it is not a powder for reconstitution.